Insulin-like growth factor-1 fails to enhance central nervous system myelin repair during autoimmune demyelination

American Journal of Pathology

Volumn 157, Issue 3, 2000, Pages 933-943

  Cannella, Barbara ^a   Pitt, David ^a   Capello, Cedric S ^b   Raine, Cedric S ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

MYELIN; SOMATOMEDIN C; TRANSFORMING GROWTH FACTOR BETA2; TRANSFORMING GROWTH FACTOR BETA3;

ADOPTIVE TRANSFER; ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNE DISEASE; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DEMYELINATION; FEMALE; IMMUNOCYTOCHEMISTRY; IMMUNOMODULATION; MOUSE; MULTIPLE SCLEROSIS; MYELINATION; NEUROPATHOLOGY; NONHUMAN; OLIGODENDROGLIA; PRIORITY JOURNAL; REMYELINIZATION;

EID: 0034495084     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)64606-8     Document Type: Article

References (26)

1. Demyelinating diseases
2. GGF/Neuregulin is a neuronal signal that promotes the proliferation and survival and inhibits the differentiation of oligodendrocyte progenitors
3. The neuregulin, glial growth factor 2, diminishes autoimmune demyelination and enhances remyelination in a chronic relapsing model for multiple sclerosis
4. Insulin-like growth factor I promotes cell proliferation and oligodendroglial commitment in rat glial progenitor cells developing in vitro
5. Developing oligodendroglia express mRNA for insulin-like growth factor-1, a regulator of oligodendrocyte development
6. Insulin-like growth factor I treatment reduces clinical deficits and lesion severity in acute demyelinating experimental autoimmune encephalomyelitis
7. Chronic relapsing experimental autoimmune encephalomyelitis: Effects of insulin-like growth factor-1 treatment on clinical deficits, lesion severity, glial responses, and blood-brain barrier defects
8. Regulation of experimental autoimmune encephalomyelitis with insulin-like growth factor (IGF-1) and IGF-1/IGF-binding protein-3 complex (IGF-1/IGFBPs)
9. Experimental autoimmune encephalomyelitis: Augmentation of demyelination by different myelin lipids
10. The morphology of myelin and myelination
11. Regulation of oligodendrocyte development and CNS myelination by growth factors: Prospects for therapy of demyelinating disease
12. Platelet-derived growth factor promotes division and motility and inhibits premature differentiation of the oligodendrocyte/type-2 astrocyte progenitor cell
13. Platelet-derived growth factor from astrocytes drives the clock that times oligodendrocyte development in culture
14. Multiple Sclerosis: Implications of re-expression of a developmental gene (uc2 MBP) for repair of chronic lesions
15. Insulin-like growth factor-1 treatment reduces demyelination and up-regulates gene expression of myelin-related proteins in experimental autoimmune encephalomyelitis
16. Insulin-like growth factor-1 stimulation of lymphopoiesis
17. Structural and functional characterization of the human T lymphocyte receptor for insulin-like growth factor 1 in vitro
18. A role for TGF-β in oligodendrocyte differentiation
19. Prevention and treatment of chronic relapsing experimental allergic encephalomyelitis by transforming growth factor-β1
20. Successful treatment of experimental allergic encephalomyelitis with transforming growth factor-β1
21. Long-term treatment of chronic relapsing experimental allergic encephalomyelitis by transforming growth factor β2
22. TGF-β2 reduces demyelination, virus antigen expression and macrophage recruitment in a viral model of multiple sclerosis
23. Differential expression of transforming growth factor-β1, β2, and β3 by glioblastoma cells, astrocytes, and microglia
24. Multiple Sclerosis: Remyelination of nascent lesions
25. Multiple Sclerosis: Remyelination in acute lesions